Payment overview · 2025
General Payments
$322.74
30 reported records · 8 companies
Healthcare provider profile · identity verified
John Fox, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEVADA, MO · NPI 1992786305
Verified facts
What the public records show
CMS Open Payments records show John Fox, M.D. received $322.74 in general payments during 2025 across 30 reported records.
ABBVIE INC. accounted for 53.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Symbicort by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 347 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $171.41 | 53.1% | 21 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.30 | 13.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.65 | 8.9% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $21.60 | 6.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.55 | 4.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.23 | 4.4% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $14.11 | 4.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.89 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $322.74 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $112.24 | 14 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $43.30 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.51 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $28.65 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $28.65 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $28.65 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $16.81 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.54 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $14.11 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
68 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
347 | 59 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 854 | 146 |
| Gabapentin | Gabapentin | 684 | 111 |
| Atorvastatin Calcium | Atorvastatin Calcium | 637 | 150 |
| Lisinopril | Lisinopril | 635 | 148 |
| Pantoprazole Sodium | Pantoprazole Sodium | 535 | 127 |
| Amlodipine Besylate | Amlodipine Besylate | 518 | 103 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 373 | 56 |
| Omeprazole | Omeprazole | 355 | 75 |
| Glimepiride | Glimepiride | 353 | 74 |
| Furosemide | Furosemide | 351 | 67 |
| Meloxicam | Meloxicam | 351 | 70 |
| Tramadol Hcl | Tramadol Hcl | 351 | 75 |
| Eliquis | Apixaban | 347 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 310 | 61 |
| Losartan Potassium | Losartan Potassium | 306 | 70 |
| Metformin Hcl | Metformin Hcl | 299 | 62 |
| Citalopram Hbr | Citalopram Hydrobromide | 298 | 56 |
| Montelukast Sodium | Montelukast Sodium | 262 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 259 | 61 |
| Trazodone Hcl | Trazodone Hcl | 259 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 255 | 45 |
| Simvastatin | Simvastatin | 246 | 57 |
| Potassium Chloride | Potassium Chloride | 237 | 47 |
| Allopurinol | Allopurinol | 230 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 211 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 209 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 199 | 49 |
| Carvedilol | Carvedilol | 197 | 46 |
| Alprazolam | Alprazolam | 187 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 185 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 181 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 167 | 43 |
| Sertraline Hcl | Sertraline Hcl | 166 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 155 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 154 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 150 | 23 |
| Lorazepam | Lorazepam | 149 | 22 |
| Morphine Sulfate Er | Morphine Sulfate | 147 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 142 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 141 | 19 |
| Pregabalin | Pregabalin | 134 | 24 |
| Celecoxib | Celecoxib | 130 | 23 |
| Methylprednisolone | Methylprednisolone | 123 | 111 |
| Ropinirole Hcl | Ropinirole Hcl | 119 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 118 | 15 |
| Donepezil Hcl | Donepezil Hcl | 117 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 28 |
| Clonazepam | Clonazepam | 109 | 18 |
| Prednisone | Prednisone | 106 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 106 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 103 | 18 |
| Famotidine | Famotidine | 101 | 20 |
| Xarelto | Rivaroxaban | 101 | 17 |
| Finasteride | Finasteride | 98 | 27 |
| Ozempic | Semaglutide | 95 | 18 |
| Fentanyl | Fentanyl | 93 | 15 |
| Divalproex Sodium | Divalproex Sodium | 92 | suppressed |
| Mirtazapine | Mirtazapine | 88 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 85 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 83 | 21 |
| Lovastatin | Lovastatin | 82 | 20 |
| Atenolol | Atenolol | 81 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 80 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 80 | 14 |
| Warfarin Sodium | Warfarin Sodium | 79 | 13 |
| Baclofen | Baclofen | 77 | 12 |
| Buspirone Hcl | Buspirone Hcl | 77 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 15 |
| Alendronate Sodium | Alendronate Sodium | 76 | 13 |
| Ondansetron Odt | Ondansetron | 76 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 15 |
| Metformin Hcl Er | Metformin Hcl | 75 | 13 |
| Myrbetriq | Mirabegron | 74 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 74 | 15 |
| Levetiracetam | Levetiracetam | 70 | suppressed |
| Levofloxacin | Levofloxacin | 68 | 62 |
| Linzess | Linaclotide | 68 | 11 |
| Jardiance | Empagliflozin | 67 | 16 |
| Olanzapine | Olanzapine | 66 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 63 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 62 | suppressed |
| Topiramate | Topiramate | 62 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 59 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 39 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 58 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 56 | 11 |
| Trulicity | Dulaglutide | 56 | suppressed |
| Estradiol | Estradiol | 55 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 55 | suppressed |
| Ezetimibe | Ezetimibe | 54 | 16 |
| Novolog Flexpen | Insulin Aspart | 54 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | suppressed |
| Paliperidone Er | Paliperidone | 51 | suppressed |
| Risperidone | Risperidone | 50 | suppressed |
| Spironolactone | Spironolactone | 50 | 14 |
| Digoxin | Digoxin | 49 | suppressed |
| Methotrexate | Methotrexate Sodium | 49 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 17 |
| Levemir Flexpen | Insulin Detemir | 45 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 21 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 43 | suppressed |
| Fluconazole | Fluconazole | 43 | 32 |
| Fenofibrate | Fenofibrate | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 41 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 41 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 41 | suppressed |
| Diazepam | Diazepam | 40 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Nystatin | Nystatin | 39 | 22 |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Ibuprofen | Ibuprofen | 38 | suppressed |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | 12 |
| Glipizide | Glipizide | 37 | suppressed |
| Sucralfate | Sucralfate | 37 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 35 | suppressed |
| Temazepam | Temazepam | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Olanzapine Odt | Olanzapine | 30 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 30 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 30 | suppressed |
| Vraylar | Cariprazine Hcl | 30 | suppressed |
| Risperidone Er | Risperidone Microspheres | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Klor-Con M20 | Potassium Chloride | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 22 |
| Invokana | Canagliflozin | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 21 | 21 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 20 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 18 |
| Torsemide | Torsemide | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Anastrozole | Anastrozole | 18 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Glyburide | Glyburide | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Leflunomide | Leflunomide | 17 | suppressed |
| Novolog | Insulin Aspart | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 16 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Dofetilide | Dofetilide | 14 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 14 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 14 | suppressed |
| Lumigan | Bimatoprost | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ursodiol | Ursodiol | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Keppra Xr | Levetiracetam | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Sprintec | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Vimpat | Lacosamide | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 11 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $322.74 · 30 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, CAPVAXIVE, COMIRNATY, GARDASIL 9, LEQVIO, MAVYRET, Omnipod, PREVNAR 20, QULIPTA, TONMYA, UBRELVY, VAXNEUVANCE, VOQUEZNA, VRAYLAR | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error